DraftKings (DKNG) and Recursion Pharmaceuticals (RXRX) are poised for a strong recovery in 2026 after underperforming in 2025. DraftKings, known for its sports betting platform, saw an 8% decline in 2025 due to slowing growth and increasing competition from prediction markets like Kalshi and Polymarket. Despite these challenges, the company's strong brand and partnerships with major sports broadcasters like NBCUniversal and ESPN position it for a comeback. DraftKings is also expanding into the prediction market business, enhancing its revenue mix.

Recursion Pharmaceuticals, with its AI-powered drug discovery platform, is set to validate its technology in 2026. The company's Recursion OS can process vast amounts of data to identify promising drug prospects, significantly reducing the time and cost of drug development. This year, Recursion is scheduled to release updates on several drugs, including two entering phase 1 clinical testing. Analysts predict a revenue increase from $63 million in 2025 to $83 million in 2026, which could help reduce the company's losses and affirm its business potential.

The recovery of these stocks hinges on their ability to leverage existing strengths and overcome recent setbacks. DraftKings' brand power and strategic partnerships provide a buffer against competition, while Recursion's innovative technology offers a competitive edge in the pharmaceutical industry. Investors are watching these developments closely, anticipating a potential rebound that could turn 2026 into a breakout year for both companies.